Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. April 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

LEXINGTON, Mass., April 23, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that...
29. März 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

LEXINGTON, Mass., March 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
11. März 2013 08:00 ET | Quelle: Curis, Inc.

Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
11. März 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
25. Februar 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
20. Februar 2013 07:00 ET | Quelle: Curis, Inc.

Curis Reports Fourth Quarter and Year-End 2012 Financial Results

LEXINGTON, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
19. Februar 2013 07:00 ET | Quelle: Curis, Inc.

Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer

- Brings Over 20 Years of Experience in Cancer Research, Drug Discovery and Development, Including Nexavar® (sorafenib) and PD-0332991 (palbociclib) - LEXINGTON, Mass., Feb. 19, 2013 (GLOBE...
15. Februar 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
13. Februar 2013 07:00 ET | Quelle: Curis, Inc.

Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013

LEXINGTON, Mass., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that...
24. Januar 2013 07:00 ET | Quelle: Curis, Inc.

Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907

LEXINGTON, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer...

Vorherige Seite